Autopsy report · NCT00362700
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
Cause of deathNo reason given
Life of this trial
- Registered 3 years 1 month after it had already started.
- Ran for about 2 years 3 months before it stopped.
- 33 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Bukwang Pharmaceutical
- Sponsor type
- Industry
- Conditions
- Hepatitis B
- Interventions
- Clevudine
- Participants
- 33
- Sites
- 7
- Countries
- South Korea
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.